GC Medical Science Corporation (KOSDAQ:142280)

Market Cap	74.47B -12.2%
Revenue (ttm)	105.48B -1.1%
Net Income	4.47B +171.8%
EPS	123.33 +304.1%
Shares Out	21.74M
PE Ratio	27.77
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	472,684
Open	3,450.00
Previous Close	3,460.00
Day's Range	3,330.00 - 3,530.00
52-Week Range	3,200.00 - 6,660.00
Beta	0.56
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About GC Medical Science

GC Medical Science Corporation operates as a diagnostic medical device company in the vitro diagnostic industry in South Korea and internationally. The company’s products include human healthcare products for the diagnosis of diabetes, non-communicable diseases, respiratory diseases, and vector borne diseases. It offers CERA-CHEK 1Code and CERA-CHEK 1070 for diabetes; GREENCARE A1c for HbA1c, CERA-CHEK 3 in 1 GHL for multi-diagnosis; CERA-CHEK Lactate; GREENCARE Hb and CERA-CHEK Hb Plus for haemoglobin; and GCare Lipid and GCare Lipid Printer f...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1972
• Employees: 122
• Stock Exchange: KOSDAQ
• Ticker Symbol: 142280

Financial Performance

In 2025, GC Medical Science's revenue was 108.41 billion, an increase of 4.39% compared to the previous year's 103.85 billion. Earnings were 3.67 billion, an increase of 2.38%.